Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome After Autotransplants for Lymphomas and Plasma Cell Myeloma

Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) developing in persons exposed to DNA-damaging agents for a prior cancer are often referred to as treatment- or therapy-related myeloid neoplasms (t-MN)[1,2]. t-MN constitute approximately 10-20% of all cases of AML and MDS[3], a proportion that may increase in the future with an increasing prevalence of cancer survivors[4,5]. Hematopoietic cell transplants (HCT) use high doses of drugs and/or ionizing radiations and can also lead to t-MN[6,7].

Source: Leukemia Research - July 19, 2018 Category: Hematology Authors: Tomas Radivoyevitch, Robert M. Dean, Bronwen E. Shaw, Ruta Brazauskas, Heather R. Tecca, Remco J. Molenaar, Minoo Battiwalla, Bipin N. Savani, Mary E.D. Flowers, Kenneth R. Cooke, Betty K. Hamilton, Matt Kalaycio, Jaroslaw P. Maciejewski, Ibrahim Ahmed, G Source Type: research